Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort*
暂无分享,去创建一个
A. d’Arminio Monforte | A. Antinori | P. Lorenzini | C. Mussini | S. Lo Caputo | F. Baldelli | M. Puoti | A. Castagna | A. Cozzi-Lepri | N. Gianotti | F. Vichi | A. Maddaloni